Sulodexide for the Prevention of Recurrent Venous Thromboembolism The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic...

Full description

Saved in:
Bibliographic Details
Published inCirculation (New York, N.Y.) Vol. 132; no. 20; pp. 1891 - 1897
Main Authors Andreozzi, Giuseppe M., Bignamini, Angelo A., Davì, Giovanni, Palareti, Gualtiero, Matuška, Jiří, Holý, Martin, Pawlaczyk-Gabriel, Katarzyna, Džupina, Andrej, Sokurenko, German Y., Didenko, Yury P., Andrei, Laurentia D., Lessiani, Gianfranco, Visonà, Adriana
Format Journal Article
LanguageEnglish
Published United States Lippincott Williams & Wilkins 17.11.2015
Subjects
Adult
Aged
Anticoagulants - administration & dosage
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Glycosaminoglycans - administration & dosage
Humans
Male
Middle Aged
Original
Recurrence
Secondary Prevention - methods
Venous Thromboembolism - diagnosis
Venous Thromboembolism - prevention & control
glycosaminoglycans
recurrence
venous thromboembolism
randomized controlled trial
Online AccessGet full text

Cover

Abstract Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known. In this multicenter, double-blind study, 615 patients with first-ever unprovoked venous thromboembolism who had completed 3 to 12 months of oral anticoagulant treatment were randomly assigned to sulodexide 500 lipasemic units twice daily or placebo for 2 years, in addition to elastic stockings. The primary efficacy outcome was recurrence of venous thromboembolism. Major or clinically relevant bleeding was the primary safety outcome. Venous thromboembolism recurred in 15 of the 307 patients who received sulodexide and in 30 of the 308 patients who received placebo (hazard ratio, 0.49; 95% confidence interval [CI], 0.27-0.92; P=0.02). The analysis in which lost to follow-up was assigned to failure yielded a risk ratio among treated versus control subjects of 0.54 (95% confidence interval, 0.35-0.85; P=0.009). No major bleeding episodes occurred; 2 patients in each treatment group had a clinically relevant bleeding episode. Adverse events were similar in the 2 groups. Sulodexide given after discontinuation of anticoagulant treatment reduced the risk of recurrence in patients with unprovoked venous thromboembolism, with no apparent increase of bleeding risk. URL: https://www.clinicaltrialsregister.eu/. Identifier: EudraCT number 2009-016923-77.
AbstractList Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known.BACKGROUNDPatients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known.In this multicenter, double-blind study, 615 patients with first-ever unprovoked venous thromboembolism who had completed 3 to 12 months of oral anticoagulant treatment were randomly assigned to sulodexide 500 lipasemic units twice daily or placebo for 2 years, in addition to elastic stockings. The primary efficacy outcome was recurrence of venous thromboembolism. Major or clinically relevant bleeding was the primary safety outcome. Venous thromboembolism recurred in 15 of the 307 patients who received sulodexide and in 30 of the 308 patients who received placebo (hazard ratio, 0.49; 95% confidence interval [CI], 0.27-0.92; P=0.02). The analysis in which lost to follow-up was assigned to failure yielded a risk ratio among treated versus control subjects of 0.54 (95% confidence interval, 0.35-0.85; P=0.009). No major bleeding episodes occurred; 2 patients in each treatment group had a clinically relevant bleeding episode. Adverse events were similar in the 2 groups.METHODS AND RESULTSIn this multicenter, double-blind study, 615 patients with first-ever unprovoked venous thromboembolism who had completed 3 to 12 months of oral anticoagulant treatment were randomly assigned to sulodexide 500 lipasemic units twice daily or placebo for 2 years, in addition to elastic stockings. The primary efficacy outcome was recurrence of venous thromboembolism. Major or clinically relevant bleeding was the primary safety outcome. Venous thromboembolism recurred in 15 of the 307 patients who received sulodexide and in 30 of the 308 patients who received placebo (hazard ratio, 0.49; 95% confidence interval [CI], 0.27-0.92; P=0.02). The analysis in which lost to follow-up was assigned to failure yielded a risk ratio among treated versus control subjects of 0.54 (95% confidence interval, 0.35-0.85; P=0.009). No major bleeding episodes occurred; 2 patients in each treatment group had a clinically relevant bleeding episode. Adverse events were similar in the 2 groups.Sulodexide given after discontinuation of anticoagulant treatment reduced the risk of recurrence in patients with unprovoked venous thromboembolism, with no apparent increase of bleeding risk.CONCLUSIONSulodexide given after discontinuation of anticoagulant treatment reduced the risk of recurrence in patients with unprovoked venous thromboembolism, with no apparent increase of bleeding risk.URL: https://www.clinicaltrialsregister.eu/. Identifier: EudraCT number 2009-016923-77.CLINICAL TRIAL REGISTRATIONURL: https://www.clinicaltrialsregister.eu/. Identifier: EudraCT number 2009-016923-77.
Supplemental Digital Content is available in the text. Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known.
Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending anticoagulation reduces the risk of recurrence but is associated with increased bleeding. Sulodexide, a glycosaminoglycan, exerts antithrombotic and profibrinolytic actions with a low bleeding risk when administered orally, but its benefit for preventing recurrent venous thromboembolism is not well known. In this multicenter, double-blind study, 615 patients with first-ever unprovoked venous thromboembolism who had completed 3 to 12 months of oral anticoagulant treatment were randomly assigned to sulodexide 500 lipasemic units twice daily or placebo for 2 years, in addition to elastic stockings. The primary efficacy outcome was recurrence of venous thromboembolism. Major or clinically relevant bleeding was the primary safety outcome. Venous thromboembolism recurred in 15 of the 307 patients who received sulodexide and in 30 of the 308 patients who received placebo (hazard ratio, 0.49; 95% confidence interval [CI], 0.27-0.92; P=0.02). The analysis in which lost to follow-up was assigned to failure yielded a risk ratio among treated versus control subjects of 0.54 (95% confidence interval, 0.35-0.85; P=0.009). No major bleeding episodes occurred; 2 patients in each treatment group had a clinically relevant bleeding episode. Adverse events were similar in the 2 groups. Sulodexide given after discontinuation of anticoagulant treatment reduced the risk of recurrence in patients with unprovoked venous thromboembolism, with no apparent increase of bleeding risk. URL: https://www.clinicaltrialsregister.eu/. Identifier: EudraCT number 2009-016923-77.
Author Andreozzi, Giuseppe M.
Holý, Martin
Palareti, Gualtiero
Pawlaczyk-Gabriel, Katarzyna
Sokurenko, German Y.
Davì, Giovanni
Matuška, Jiří
Visonà, Adriana
Didenko, Yury P.
Džupina, Andrej
Lessiani, Gianfranco
Bignamini, Angelo A.
Andrei, Laurentia D.
Author_xml – sequence: 1
  givenname: Giuseppe M.
  surname: Andreozzi
  fullname: Andreozzi, Giuseppe M.
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 2
  givenname: Angelo A.
  surname: Bignamini
  fullname: Bignamini, Angelo A.
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 3
  givenname: Giovanni
  surname: Davì
  fullname: Davì, Giovanni
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 4
  givenname: Gualtiero
  surname: Palareti
  fullname: Palareti, Gualtiero
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 5
  givenname: Jiří
  surname: Matuška
  fullname: Matuška, Jiří
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 6
  givenname: Martin
  surname: Holý
  fullname: Holý, Martin
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 7
  givenname: Katarzyna
  surname: Pawlaczyk-Gabriel
  fullname: Pawlaczyk-Gabriel, Katarzyna
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 8
  givenname: Andrej
  surname: Džupina
  fullname: Džupina, Andrej
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 9
  givenname: German Y.
  surname: Sokurenko
  fullname: Sokurenko, German Y.
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 10
  givenname: Yury P.
  surname: Didenko
  fullname: Didenko, Yury P.
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 11
  givenname: Laurentia D.
  surname: Andrei
  fullname: Andrei, Laurentia D.
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 12
  givenname: Gianfranco
  surname: Lessiani
  fullname: Lessiani, Gianfranco
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
– sequence: 13
  givenname: Adriana
  surname: Visonà
  fullname: Visonà, Adriana
  organization: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, “G. D’Annunzio” University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice–Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26408273$$D View this record in MEDLINE/PubMed
BookMark eNqFUU1PxCAUJEaj6-pfMPXmpQqUQrlomo0fm2zU6OqV0PbVxbRFod3ov5fNqlEvHgh5j3kzzJtdtNnZDhA6JPiYEE5OJtO7ycMsn09vrvOrPPTSY0y4TPAGGpGUspilidxEI4yxjEVC6Q7a9f45lDwR6TbaoZzhjIpkhPL7obEVvJkKotq6qF9AdOtgCV1vbBfZOrqDcnAu1NEjdHbw0XzhbFtYCKcxvt1DW7VuPOx_3mP0cHE-n1zFs5vL6SSfxWUiaB_XXHJKpSaSMZJBClrWmPKKaMpEkUogZSaAiLKogkWua03DHAhWVVjTrEjG6HTN-zIULVRl-JHTjXpxptXuXVlt1O-XzizUk10qxllwjQPB0SeBs68D-F61xpfQNLqD4EsRkTCaEUmyAD34qfUt8rW3ADhbA0pnvXdQq9L0erWyIG0aRbBaJaV-JxV6qVonFRjkH4Yvkf9nPwD1z5sb
CitedBy_id crossref_primary_10_17116_profmed20212404145
crossref_primary_10_1177_0885066618796486
crossref_primary_10_4103_2589_9686_325188
crossref_primary_10_1016_j_jsps_2018_03_003
crossref_primary_10_1093_eurheartj_ehz405
crossref_primary_10_32345_USMYJ_3_149__2024_93_107
crossref_primary_10_23736_S0392_9590_22_04970_7
crossref_primary_10_1016_S0140_6736_16_30514_1
crossref_primary_10_1097_FJC_0000000000000799
crossref_primary_10_2478_ahp_2018_0009
crossref_primary_10_3389_fmed_2025_1519604
crossref_primary_10_1177_10760296211049402
crossref_primary_10_1055_a_1562_7599
crossref_primary_10_23736_S0392_9590_24_05339_2
crossref_primary_10_17116_flebo202115031211
crossref_primary_10_1182_blood_2017_07_798306
crossref_primary_10_1055_a_1414_5216
crossref_primary_10_1161_CIRCULATIONAHA_115_019310
crossref_primary_10_1007_s10143_025_03409_0
crossref_primary_10_1055_s_0040_1716874
crossref_primary_10_23736_S1593_232X_20_00469_5
crossref_primary_10_36290_far_2017_014
crossref_primary_10_33529_ANGI02020301
crossref_primary_10_1161_CIRCULATIONAHA_115_020061
crossref_primary_10_1177_1076029620945792
crossref_primary_10_1177_1753466619878556
crossref_primary_10_1016_j_redar_2016_09_007
crossref_primary_10_17116_flebo202014031196
crossref_primary_10_36290_int_2018_058
crossref_primary_10_17116_flebo202014041275
crossref_primary_10_1016_j_rec_2019_12_022
crossref_primary_10_23736_S0392_9590_23_05110_6
crossref_primary_10_1055_s_0042_1744302
crossref_primary_10_1080_14779072_2016_1248406
crossref_primary_10_1016_j_ejvs_2020_09_023
crossref_primary_10_1016_S2352_3026_21_00105_8
crossref_primary_10_1080_14779072_2020_1755260
crossref_primary_10_1183_13993003_01647_2019
crossref_primary_10_38109_2225_1685_2021_1_44_77
crossref_primary_10_23736_S0392_9590_18_03997_4
crossref_primary_10_1007_s00381_020_04958_z
crossref_primary_10_1055_a_1690_8728
crossref_primary_10_23736_S1593_232X_19_00439_9
crossref_primary_10_36106_ijsr_8746403
crossref_primary_10_33667_2078_5631_2021_7_46_50
crossref_primary_10_1080_17474086_2017_1366851
crossref_primary_10_1016_j_thromres_2022_12_005
crossref_primary_10_3390_jcm12031019
crossref_primary_10_1093_eurheartj_ehx003
crossref_primary_10_1177_1076029620954913
crossref_primary_10_33920_med_10_2303_05
crossref_primary_10_1177_1076029619878786
crossref_primary_10_21518_1995_1477_2018_3_4_83_88
crossref_primary_10_1371_journal_pone_0214134
crossref_primary_10_1007_s12185_023_03651_6
crossref_primary_10_3390_jcm13082332
crossref_primary_10_1016_S2352_3026_20_30211_8
crossref_primary_10_1111_jth_14324
crossref_primary_10_1016_j_rceng_2024_10_004
crossref_primary_10_1016_j_rce_2017_02_017
crossref_primary_10_1097_FJC_0000000000000778
crossref_primary_10_3389_fphar_2018_00876
crossref_primary_10_1016_j_jvsv_2020_06_019
crossref_primary_10_1002_14651858_CD011088_pub2
crossref_primary_10_1021_acs_biomac_8b00691
crossref_primary_10_1159_000499879
crossref_primary_10_17116_flebo202317031152
crossref_primary_10_1024_0301_1526_a000932
crossref_primary_10_14797_mdcvj_1338
crossref_primary_10_33667_2078_5631_2019_3_25_400__37_42
crossref_primary_10_1053_j_tvir_2017_07_004
crossref_primary_10_36290_int_2017_042
crossref_primary_10_1016_j_ejim_2021_04_004
crossref_primary_10_1016_j_recesp_2019_12_011
crossref_primary_10_1007_s11739_020_02381_5
crossref_primary_10_1177_1708538118776896
crossref_primary_10_23736_S2724_5683_21_05914_7
crossref_primary_10_1016_j_thromres_2017_04_002
crossref_primary_10_33920_med_10_2206_06
crossref_primary_10_1136_bmjresp_2023_001856
crossref_primary_10_1152_japplphysiol_00024_2022
crossref_primary_10_2478_ahp_2018_0013
crossref_primary_10_1016_j_bbadis_2016_07_018
crossref_primary_10_1080_14656566_2016_1268122
crossref_primary_10_1080_17474086_2020_1770589
crossref_primary_10_1007_s12325_020_01270_9
crossref_primary_10_1016_j_rce_2024_07_007
crossref_primary_10_1016_j_rceng_2017_04_003
crossref_primary_10_1055_s_0044_1791232
crossref_primary_10_1111_jth_14570
crossref_primary_10_1007_s12325_020_01232_1
crossref_primary_10_1007_s11739_016_1521_8
crossref_primary_10_23888_PAVLOVJ2020284548_566
crossref_primary_10_1016_j_thromres_2016_05_022
crossref_primary_10_1097_MBC_0000000000000697
Cites_doi 10.1160/TH13-09-0793
10.1056/NEJMoa0906598
10.1055/s-0037-1613116
10.1016/0049-3848(94)90267-4
10.1056/NEJMoa1114238
10.1056/NEJMoa1210384
10.1016/0735-1097(94)90498-7
10.1056/NEJMoa1302507
10.2147/DDDT.S6762
10.1267/THRO88030402
10.1177/000331970605700108
10.1056/NEJMoa1007903
10.1056/NEJMoa1113697
10.1056/NEJMoa064247
10.1177/1076029609333674
10.7326/0003-4819-125-1-199607010-00001
10.1378/chest.11-2301
10.1177/000331970405500302
10.1056/NEJMoa1306638
10.1056/NEJMoa1207541
10.1056/NEJM200107193450302
10.1267/THRO06030562
10.1056/NEJM199903253401201
10.1055/s-0038-1650713
10.2165/11599360-000000000-00000
10.1007/s11239-007-0103-z
10.1056/NEJM199903253401209
10.7326/0003-4819-139-1-200307010-00008
10.1056/NEJM199506223322501
ContentType Journal Article
Contributor Madycki, Grzegorz
Tatiana, Vorontsova
Sergey, Basos
Nikolaevna, Matevosyan Elena
Zotta, Laura
Lesiak, Tomasz
Ivanovich, Kirienko Alexander
Wasiewicz, Mirosla
Valeria, Korzhova
Ruslan, Linchak
Temirlan, Gamzatov
Valerii, Melnik
Džupina, Andrej
Andrei, Laurentia Doina
Svetlana, Androsova
Failla, Giacomo
Vladimir, Popovich
Vladimirovich, Svetlikov Alexei
Mikhailovich, Sarana Andrey
Pereira, Albino
Arpaia, Guido Giuseppe
Martini, Romeo
Hirmerova, Jana
Yurievich, Malygin Alexander
Parisi, Roberto
Hruboň, Antonín
Mikosiński, Jacek
Holý, Martin
Addolorata, S Giovanni
Pecháček, Václav
Śmigielski, Jacek
Roztočil, Karel
Davì, Giovanni
Visonà, Adriana
Mikhail, Gladchenko
Blaj, Stefan
Tonello, Chiara
Alina, Agafina
Camporese, Giuseppe
Feliksovna, Balluzek Marina
Sajkowski, Marek
Gabriel, Marcin
Krasiński, Zbigniew
Nikolaevich, Sonkin Igor
Pavlovich, Didenko Yury
Aleksandrovna, Chernyatina Marina
Ospedaliero, Presidio
Niedziela, Piotr
Militaru, Constantin
Pawlaczyk-Gabriel, Katarzyna
Stoenescu, Radu Dumitru
Ferrara, Filippo
Vladimirovich, Rodoman Gr
Contributor_xml – sequence: 1
  givenname: Karel
  surname: Roztočil
  fullname: Roztočil, Karel
– sequence: 2
  givenname: Jana
  surname: Hirmerova
  fullname: Hirmerova, Jana
– sequence: 3
  givenname: Jiří
  surname: Matuška
  fullname: Matuška, Jiří
– sequence: 4
  givenname: Václav
  surname: Pecháček
  fullname: Pecháček, Václav
– sequence: 5
  givenname: Martin
  surname: Holý
  fullname: Holý, Martin
– sequence: 6
  givenname: Tomasz
  surname: Urbanek
  fullname: Urbanek, Tomasz
– sequence: 7
  givenname: Jacek
  surname: Śmigielski
  fullname: Śmigielski, Jacek
– sequence: 8
  givenname: Jacek
  surname: Mikosiński
  fullname: Mikosiński, Jacek
– sequence: 9
  givenname: Mirosla
  surname: Wasiewicz
  fullname: Wasiewicz, Mirosla
– sequence: 10
  givenname: Tomasz
  surname: Lesiak
  fullname: Lesiak, Tomasz
– sequence: 11
  givenname: Piotr
  surname: Niedziela
  fullname: Niedziela, Piotr
– sequence: 12
  givenname: Marek
  surname: Sajkowski
  fullname: Sajkowski, Marek
– sequence: 13
  givenname: Grzegorz
  surname: Madycki
  fullname: Madycki, Grzegorz
– sequence: 14
  givenname: Katarzyna
  surname: Pawlaczyk-Gabriel
  fullname: Pawlaczyk-Gabriel, Katarzyna
– sequence: 15
  givenname: Marcin
  surname: Gabriel
  fullname: Gabriel, Marcin
– sequence: 16
  givenname: Zbigniew
  surname: Krasiński
  fullname: Krasiński, Zbigniew
– sequence: 17
  givenname: Andrej
  surname: Džupina
  fullname: Džupina, Andrej
– sequence: 18
  givenname: Antonín
  surname: Hruboň
  fullname: Hruboň, Antonín
– sequence: 19
  givenname: Miroslav
  surname: Urban
  fullname: Urban, Miroslav
– sequence: 20
  givenname: Ivar
  surname: Vacula
  fullname: Vacula, Ivar
– sequence: 21
  givenname: Kirienko Alexander
  surname: Ivanovich
  fullname: Ivanovich, Kirienko Alexander
– sequence: 22
  givenname: Balluzek Marina
  surname: Feliksovna
  fullname: Feliksovna, Balluzek Marina
– sequence: 23
  givenname: Basos
  surname: Sergey
  fullname: Sergey, Basos
– sequence: 24
  givenname: Chernyatina Marina
  surname: Aleksandrovna
  fullname: Aleksandrovna, Chernyatina Marina
– sequence: 25
  givenname: Gladchenko
  surname: Mikhail
  fullname: Mikhail, Gladchenko
– sequence: 26
  givenname: Didenko Yury
  surname: Pavlovich
  fullname: Pavlovich, Didenko Yury
– sequence: 27
  givenname: Androsova
  surname: Svetlana
  fullname: Svetlana, Androsova
– sequence: 28
  givenname: Fokin Alexey
  surname: Anatolievich
  fullname: Anatolievich, Fokin Alexey
– sequence: 29
  givenname: Degtyarev
  surname: Maxim
  fullname: Maxim, Degtyarev
– sequence: 30
  givenname: Malygin Alexander
  surname: Yurievich
  fullname: Yurievich, Malygin Alexander
– sequence: 31
  givenname: Korzhova
  surname: Valeria
  fullname: Valeria, Korzhova
– sequence: 32
  givenname: Matevosyan Elena
  surname: Nikolaevna
  fullname: Nikolaevna, Matevosyan Elena
– sequence: 33
  givenname: Vorontsova
  surname: Tatiana
  fullname: Tatiana, Vorontsova
– sequence: 34
  givenname: Sarana Andrey
  surname: Mikhailovich
  fullname: Mikhailovich, Sarana Andrey
– sequence: 35
  givenname: Agafina
  surname: Alina
  fullname: Alina, Agafina
– sequence: 36
  givenname: Sokurenko
  surname: German Yurievich
  fullname: German Yurievich, Sokurenko
– sequence: 37
  givenname: Popovich
  surname: Vladimir
  fullname: Vladimir, Popovich
– sequence: 38
  givenname: Stoyko Yuriy
  surname: Mikhailovich
  fullname: Mikhailovich, Stoyko Yuriy
– sequence: 39
  givenname: Linchak
  surname: Ruslan
  fullname: Ruslan, Linchak
– sequence: 40
  givenname: Svetlikov Alexei
  surname: Vladimirovich
  fullname: Vladimirovich, Svetlikov Alexei
– sequence: 41
  givenname: Gamzatov
  surname: Temirlan
  fullname: Temirlan, Gamzatov
– sequence: 42
  givenname: Esipenko Viktor
  surname: Vasilievich
  fullname: Vasilievich, Esipenko Viktor
– sequence: 43
  givenname: Rodoman Grigory
  surname: Vladimirovich
  fullname: Vladimirovich, Rodoman Grigory
– sequence: 44
  givenname: Zakhovskaya
  surname: Elena
  fullname: Elena, Zakhovskaya
– sequence: 45
  givenname: Sonkin Igor
  surname: Nikolaevich
  fullname: Nikolaevich, Sonkin Igor
– sequence: 46
  givenname: Melnik
  surname: Valerii
  fullname: Valerii, Melnik
– sequence: 47
  givenname: Constantin
  surname: Militaru
  fullname: Militaru, Constantin
– sequence: 48
  givenname: Radu Dumitru
  surname: Stoenescu
  fullname: Stoenescu, Radu Dumitru
– sequence: 49
  givenname: Blaj
  surname: Stefan
  fullname: Stefan, Blaj
– sequence: 50
  givenname: Stefan
  surname: Blaj
  fullname: Blaj, Stefan
– sequence: 51
  givenname: Laurentia Doina
  surname: Andrei
  fullname: Andrei, Laurentia Doina
– sequence: 52
  givenname: Pulido
  surname: Valente
  fullname: Valente, Pulido
– sequence: 53
  givenname: Albino
  surname: Pereira
  fullname: Pereira, Albino
– sequence: 54
  givenname: Giovanni
  surname: Davì
  fullname: Davì, Giovanni
– sequence: 55
  givenname: Gianfranco
  surname: Lessiani
  fullname: Lessiani, Gianfranco
– sequence: 56
  givenname: Giuseppe
  surname: Camporese
  fullname: Camporese, Giuseppe
– sequence: 57
  givenname: Romeo
  surname: Martini
  fullname: Martini, Romeo
– sequence: 58
  givenname: Chiara
  surname: Tonello
  fullname: Tonello, Chiara
– sequence: 59
  givenname: Presidio
  surname: Ospedaliero
  fullname: Ospedaliero, Presidio
– sequence: 60
  givenname: Adriana
  surname: Visonà
  fullname: Visonà, Adriana
– sequence: 61
  givenname: Laura
  surname: Zotta
  fullname: Zotta, Laura
– sequence: 62
  givenname: Roberto
  surname: Parisi
  fullname: Parisi, Roberto
– sequence: 63
  givenname: Guido Giuseppe
  surname: Arpaia
  fullname: Arpaia, Guido Giuseppe
– sequence: 64
  givenname: Gabriella
  surname: Spezzigu
  fullname: Spezzigu, Gabriella
– sequence: 65
  givenname: S Giovanni
  surname: Addolorata
  fullname: Addolorata, S Giovanni
– sequence: 66
  givenname: Claudio
  surname: Allegra
  fullname: Allegra, Claudio
– sequence: 67
  givenname: Filippo
  surname: Ferrara
  fullname: Ferrara, Filippo
– sequence: 68
  givenname: Corrado
  surname: Amato
  fullname: Amato, Corrado
– sequence: 69
  givenname: Giacomo
  surname: Failla
  fullname: Failla, Giacomo
Copyright 2015 The Authors.
2015 The Authors. 2015
Copyright_xml – notice: 2015 The Authors.
– notice: 2015 The Authors. 2015
CorporateAuthor SURVET Study Investigators
CorporateAuthor_xml – name: SURVET Study Investigators
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1161/CIRCULATIONAHA.115.016930
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1524-4539
EndPage 1897
ExternalDocumentID PMC4643750
26408273
10_1161_CIRCULATIONAHA_115_016930
Genre Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.-D
.3C
.XZ
.Z2
01R
0R~
0ZK
18M
1J1
29B
2FS
2WC
354
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
6PF
71W
77Y
7O~
AAAAV
AAAXR
AAFWJ
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AASXQ
AAUEB
AAWTL
AAXQO
AAYXX
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABPMR
ABPXF
ABQRW
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACCJW
ACDDN
ACDOF
ACEWG
ACGFO
ACGFS
ACILI
ACLDA
ACOAL
ACRKK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADCYY
ADGGA
ADHPY
AE3
AE6
AEBDS
AEETU
AENEX
AFBFQ
AFCHL
AFDTB
AFEXH
AFMBP
AFNMH
AFSOK
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHQVU
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
ASPBG
AVWKF
AYCSE
AZFZN
BAWUL
BOYCO
BQLVK
BYPQX
C45
CITATION
CS3
DIK
DIWNM
DU5
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JF9
JG8
JK3
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
O9-
OAG
OAH
OBH
OCB
ODMTH
OGEVE
OHH
OHYEH
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P2P
PQQKQ
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
UPT
V2I
VVN
W2D
W3M
W8F
WH7
WOQ
WOW
X3V
X3W
XXN
XYM
YFH
YOC
YSK
YYM
YZZ
ZFV
ZY1
ZZMQN
~H1
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADSXY
ID FETCH-LOGICAL-c372t-f696229a194418e5ea9f026d1a247b59e1c87e17cbd1616afa2372e74dd0a28b3
ISSN 0009-7322
1524-4539
IngestDate Thu Aug 21 14:35:57 EDT 2025
Fri Jul 11 15:15:40 EDT 2025
Mon Jul 21 05:50:06 EDT 2025
Tue Jul 01 03:20:46 EDT 2025
Thu Apr 24 23:13:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 20
Keywords glycosaminoglycans
recurrence
venous thromboembolism
randomized controlled trial
Language English
License 2015 The Authors.
Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c372t-f696229a194418e5ea9f026d1a247b59e1c87e17cbd1616afa2372e74dd0a28b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC4643750
PMID 26408273
PQID 1734281918
PQPubID 23479
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4643750
proquest_miscellaneous_1734281918
pubmed_primary_26408273
crossref_citationtrail_10_1161_CIRCULATIONAHA_115_016930
crossref_primary_10_1161_CIRCULATIONAHA_115_016930
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-11-17
PublicationDateYYYYMMDD 2015-11-17
PublicationDate_xml – month: 11
  year: 2015
  text: 2015-11-17
  day: 17
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Circulation (New York, N.Y.)
PublicationTitleAlternate Circulation
PublicationYear 2015
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
References e_1_3_4_3_2
e_1_3_4_2_2
Stevenson M (e_1_3_4_29_2) 2013
e_1_3_4_9_2
e_1_3_4_8_2
e_1_3_4_7_2
e_1_3_4_6_2
e_1_3_4_5_2
e_1_3_4_4_2
e_1_3_4_22_2
e_1_3_4_23_2
R Core Team (e_1_3_4_30_2) 2013
Hoppensteadt DA (e_1_3_4_20_2) 2014; 33
e_1_3_4_21_2
e_1_3_4_26_2
e_1_3_4_27_2
e_1_3_4_24_2
e_1_3_4_28_2
Masola V (e_1_3_4_25_2) 2014; 33
e_1_3_4_11_2
e_1_3_4_34_2
e_1_3_4_12_2
e_1_3_4_33_2
e_1_3_4_32_2
e_1_3_4_10_2
e_1_3_4_31_2
e_1_3_4_15_2
e_1_3_4_16_2
e_1_3_4_13_2
e_1_3_4_14_2
e_1_3_4_19_2
e_1_3_4_17_2
e_1_3_4_18_2
23216615 - N Engl J Med. 2013 Feb 21;368(8):699-708
16525588 - Thromb Haemost. 2006 Mar;95(3):562-6
12083500 - Thromb Haemost. 2002 Jun;87(6):947-52
22329592 - Am J Cardiovasc Drugs. 2012 Apr 1;12(2):73-81
15156256 - Angiology. 2004 May-Jun;55(3):243-9
8972038 - Thromb Haemost. 1996 Dec;76(6):1102-7
23121403 - N Engl J Med. 2012 Nov 22;367(21):1979-87
19910295 - Clin Appl Thromb Hemost. 2009 Oct;15(5):596-8
26408272 - Circulation. 2015 Nov 17;132(20):1856-9
12353067 - Thromb Haemost. 2002 Sep;88(3):402-6
7760866 - N Engl J Med. 1995 Jun 22;332(25):1661-5
12834314 - Ann Intern Med. 2003 Jul 1;139(1):19-25
26461966 - Nat Rev Cardiol. 2015 Dec;12(12):682
19966341 - N Engl J Med. 2009 Dec 10;361(24):2342-52
11463010 - N Engl J Med. 2001 Jul 19;345(3):165-9
22621626 - N Engl J Med. 2012 May 24;366(21):1959-67
8085247 - Thromb Res. 1994 Jun 1;74(5):463-75
8277091 - J Am Coll Cardiol. 1994 Jan;23(1):27-34
24936533 - Int Angiol. 2014 Jun;33(3):243-54
21128814 - N Engl J Med. 2010 Dec 23;363(26):2499-510
23991658 - N Engl J Med. 2013 Oct 10;369(15):1406-15
24391440 - Drug Des Devel Ther. 2014;8:49-65
24695909 - Thromb Haemost. 2014 Aug;112(2):255-63
22315268 - Chest. 2012 Feb;141(2 Suppl):e419S-94S
10089183 - N Engl J Med. 1999 Mar 25;340(12):901-7
23425163 - N Engl J Med. 2013 Feb 21;368(8):709-18
10089190 - N Engl J Med. 1999 Mar 25;340(12):955-6
8644983 - Ann Intern Med. 1996 Jul 1;125(1):1-7
24936531 - Int Angiol. 2014 Jun;33(3):229-35
23808982 - N Engl J Med. 2013 Aug 29;369(9):799-808
17855670 - N Engl J Med. 2007 Sep 13;357(11):1094-104
16444457 - Angiology. 2006 Jan-Feb;57(1):53-64
17906973 - J Thromb Thrombolysis. 2008 Feb;25(1):37-44
References_xml – volume-title: epiR: An R package for the analysis of epidemiological data. R package version 0.9-48
  year: 2013
  ident: e_1_3_4_29_2
– ident: e_1_3_4_34_2
  doi: 10.1160/TH13-09-0793
– ident: e_1_3_4_10_2
  doi: 10.1056/NEJMoa0906598
– ident: e_1_3_4_18_2
  doi: 10.1055/s-0037-1613116
– ident: e_1_3_4_21_2
  doi: 10.1016/0049-3848(94)90267-4
– ident: e_1_3_4_31_2
  doi: 10.1056/NEJMoa1114238
– ident: e_1_3_4_32_2
  doi: 10.1056/NEJMoa1210384
– ident: e_1_3_4_17_2
  doi: 10.1016/0735-1097(94)90498-7
– volume: 33
  start-page: 243
  year: 2014
  ident: e_1_3_4_25_2
  article-title: Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects.
  publication-title: Int Angiol
– ident: e_1_3_4_12_2
  doi: 10.1056/NEJMoa1302507
– ident: e_1_3_4_16_2
  doi: 10.2147/DDDT.S6762
– ident: e_1_3_4_27_2
  doi: 10.1267/THRO88030402
– ident: e_1_3_4_26_2
  doi: 10.1177/000331970605700108
– ident: e_1_3_4_11_2
  doi: 10.1056/NEJMoa1007903
– ident: e_1_3_4_15_2
  doi: 10.1056/NEJMoa1113697
– ident: e_1_3_4_28_2
  doi: 10.1056/NEJMoa064247
– ident: e_1_3_4_23_2
  doi: 10.1177/1076029609333674
– ident: e_1_3_4_3_2
  doi: 10.7326/0003-4819-125-1-199607010-00001
– ident: e_1_3_4_9_2
  doi: 10.1378/chest.11-2301
– ident: e_1_3_4_19_2
  doi: 10.1177/000331970405500302
– ident: e_1_3_4_13_2
  doi: 10.1056/NEJMoa1306638
– volume: 33
  start-page: 229
  year: 2014
  ident: e_1_3_4_20_2
  article-title: Pharmacological profile of sulodexide.
  publication-title: Int Angiol
– ident: e_1_3_4_14_2
  doi: 10.1056/NEJMoa1207541
– ident: e_1_3_4_5_2
  doi: 10.1056/NEJM200107193450302
– ident: e_1_3_4_33_2
  doi: 10.1267/THRO06030562
– ident: e_1_3_4_6_2
  doi: 10.1056/NEJM199903253401201
– ident: e_1_3_4_22_2
  doi: 10.1055/s-0038-1650713
– ident: e_1_3_4_24_2
  doi: 10.2165/11599360-000000000-00000
– ident: e_1_3_4_8_2
  doi: 10.1007/s11239-007-0103-z
– ident: e_1_3_4_2_2
  doi: 10.1056/NEJM199903253401209
– ident: e_1_3_4_7_2
  doi: 10.7326/0003-4819-139-1-200307010-00008
– volume-title: R: A language and environment for statistical computing
  year: 2013
  ident: e_1_3_4_30_2
– ident: e_1_3_4_4_2
  doi: 10.1056/NEJM199506223322501
– reference: 17855670 - N Engl J Med. 2007 Sep 13;357(11):1094-104
– reference: 17906973 - J Thromb Thrombolysis. 2008 Feb;25(1):37-44
– reference: 8644983 - Ann Intern Med. 1996 Jul 1;125(1):1-7
– reference: 19966341 - N Engl J Med. 2009 Dec 10;361(24):2342-52
– reference: 23991658 - N Engl J Med. 2013 Oct 10;369(15):1406-15
– reference: 22621626 - N Engl J Med. 2012 May 24;366(21):1959-67
– reference: 21128814 - N Engl J Med. 2010 Dec 23;363(26):2499-510
– reference: 24936531 - Int Angiol. 2014 Jun;33(3):229-35
– reference: 26408272 - Circulation. 2015 Nov 17;132(20):1856-9
– reference: 12083500 - Thromb Haemost. 2002 Jun;87(6):947-52
– reference: 12353067 - Thromb Haemost. 2002 Sep;88(3):402-6
– reference: 22329592 - Am J Cardiovasc Drugs. 2012 Apr 1;12(2):73-81
– reference: 23121403 - N Engl J Med. 2012 Nov 22;367(21):1979-87
– reference: 23808982 - N Engl J Med. 2013 Aug 29;369(9):799-808
– reference: 11463010 - N Engl J Med. 2001 Jul 19;345(3):165-9
– reference: 7760866 - N Engl J Med. 1995 Jun 22;332(25):1661-5
– reference: 23216615 - N Engl J Med. 2013 Feb 21;368(8):699-708
– reference: 8972038 - Thromb Haemost. 1996 Dec;76(6):1102-7
– reference: 22315268 - Chest. 2012 Feb;141(2 Suppl):e419S-94S
– reference: 23425163 - N Engl J Med. 2013 Feb 21;368(8):709-18
– reference: 26461966 - Nat Rev Cardiol. 2015 Dec;12(12):682
– reference: 15156256 - Angiology. 2004 May-Jun;55(3):243-9
– reference: 8277091 - J Am Coll Cardiol. 1994 Jan;23(1):27-34
– reference: 12834314 - Ann Intern Med. 2003 Jul 1;139(1):19-25
– reference: 24391440 - Drug Des Devel Ther. 2014;8:49-65
– reference: 16444457 - Angiology. 2006 Jan-Feb;57(1):53-64
– reference: 24936533 - Int Angiol. 2014 Jun;33(3):243-54
– reference: 8085247 - Thromb Res. 1994 Jun 1;74(5):463-75
– reference: 16525588 - Thromb Haemost. 2006 Mar;95(3):562-6
– reference: 10089190 - N Engl J Med. 1999 Mar 25;340(12):955-6
– reference: 19910295 - Clin Appl Thromb Hemost. 2009 Oct;15(5):596-8
– reference: 24695909 - Thromb Haemost. 2014 Aug;112(2):255-63
– reference: 10089183 - N Engl J Med. 1999 Mar 25;340(12):901-7
SSID ssj0006375
Score 2.5158768
Snippet Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after discontinuation of anticoagulant therapy. Extending...
Supplemental Digital Content is available in the text. Patients with a first episode of unprovoked venous thromboembolism have a high risk of recurrence after...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1891
SubjectTerms Adult
Aged
Anticoagulants - administration & dosage
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Glycosaminoglycans - administration & dosage
Humans
Male
Middle Aged
Original
Recurrence
Secondary Prevention - methods
Venous Thromboembolism - diagnosis
Venous Thromboembolism - prevention & control
Subtitle The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Title Sulodexide for the Prevention of Recurrent Venous Thromboembolism
URI https://www.ncbi.nlm.nih.gov/pubmed/26408273
https://www.proquest.com/docview/1734281918
https://pubmed.ncbi.nlm.nih.gov/PMC4643750
Volume 132
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9pAEF4lqRT1UrVJH_QRbaSqaiWcYnv9yo2QNLRqeiAQ5YbW9jixZGxEIVL4r_0vnfEa20CQ0h5AaO0dBDOfPTP-Zoaxj6H0QlNSNQ4aiCakMDSpC9AgMnTfBTc0XapGvvhldwfix7V1vbV9UGMtzab-UTB_sK7kf7SKa6hXqpL9B82WQnEBP6N-8R01jO-P0vHlLKGK9DiEki24aMmk3MAeZdPz_ktXqhdr_3aSjfwM8JXUOBc1QTFdPzBIDolOt0naKcAYReK5hUBqa4K-6uWgd3XWp0wD8RPvVdl7XuNLJNBizLJMw2wUz1WWFR14PwHtBL1d5dFSWt_PtI6i0CfoD_fpn6w70Z14EhRTxx4aJrSU3AgnkM3nOWXhPJ79hvEYqgTwSXyTSmquoqidN5BkVW73VN7lLIKO2pvd0XSn6olbQuOBldyZxB8Ik6yeQdEtKiVUBaNHUFz1DaEJS3VVKm8LVd6VwvNW7Sqvu2rC2Prtx6bbT-d7rzP4qZoZd9u4Sp1haeRkfQ9qYDzK7RJdUvTD1ECXld7fi0Pb7ImBYRBN6Di_rihMtulYu-yw-OavG7-XOl4Xkpbdr7WYapUaXPO1-s_ZsyJI4m1l8S_YFqR7bL-dymk2uuefeE5bzp8H7bHdi4Idss_-VGbMEQ8c8cArC-ZZxEsL5goPfAUPx7gAvCYmTnmJho2yCA2c0MArNPDPCgtfeI6EY97mNRw0eYWCJq9joMnXEcBzBLxkg29n_U5XK8aXaIHpGFMtsj3bMDypexhyuGCB9KKWYYe6NITjWx7ogeuA7gR-iNqzZSQN3AeOCMOWNFzffMV20iyFN4w7GHfYjicjEZgC_UlJ7AUhHRfsyDdb0GDuQqvDoOjtTyNmkmEe49v6cNk2cM0aKttoMKPcOlYNbh6z6XBhOkO8HdEzRpkCqm2oO6agZ_O622CvlSmVYhc22GDOkpGVJ1Cr--UjaXybt7wXxC-wWm83ynzHnlbQfs92ppMZfMBwYeof5Jj5C4sHFuQ
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sulodexide+for+the+Prevention+of+Recurrent+Venous+Thromboembolism%3A+The+Sulodexide+in+Secondary+Prevention+of+Recurrent+Deep+Vein+Thrombosis+%28SURVET%29+Study%3A+A+Multicenter%2C+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Trial&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Andreozzi%2C+Giuseppe+M&rft.au=Bignamini%2C+Angelo+A&rft.au=Dav%C3%AC%2C+Giovanni&rft.au=Palareti%2C+Gualtiero&rft.date=2015-11-17&rft.eissn=1524-4539&rft.volume=132&rft.issue=20&rft.spage=1891&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.115.016930&rft_id=info%3Apmid%2F26408273&rft.externalDocID=26408273
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon